{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["56"],"submitter":["Mastrantoni L"],"pubmed_abstract":["Background
In hormone-receptor positive/HER2-negative metastatic breast cancer (mBC) no randomized comparisons are available between CDK4/6 inhibitors. We undertook this systematic review and meta-analysis to assess the reliability of the likelihood of being helped or harmed (LHH).Methods
PubMed, CENTRAL, Embase and oncological meetings websites were searched to September 13th, 2022. We included phase III randomized controlled trials (RCTs) investigating palbociclib, ribociclib and abemaciclib in addition to endocrine therapy (ET) compared to placebo in hormone-receptor positive/HER2-negative advanced or mBC. Outcomes were progression-free survival (PFS), overall survival (OS), adverse events (AEs), dose reductions and discontinuations. Hazard ratios (HRs) and risk differen"],"journal":["EClinicalMedicine"],"pagination":["101824"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9874016"],"repository":["biostudies-literature"],"pubmed_title":["The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis."],"pmcid":["PMC9874016"],"pubmed_authors":["Giannarelli D","Orlandi A","Palazzo A","Daniele G","Tortora G","Mastrantoni L","Bria E","Fabi A","Garufi G"],"additional_accession":[]},"is_claimable":false,"name":"The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.","description":"Background
In hormone-receptor positive/HER2-negative metastatic breast cancer (mBC) no randomized comparisons are available between CDK4/6 inhibitors. We undertook this systematic review and meta-analysis to assess the reliability of the likelihood of being helped or harmed (LHH).Methods
PubMed, CENTRAL, Embase and oncological meetings websites were searched to September 13th, 2022. We included phase III randomized controlled trials (RCTs) investigating palbociclib, ribociclib and abemaciclib in addition to endocrine therapy (ET) compared to placebo in hormone-receptor positive/HER2-negative advanced or mBC. Outcomes were progression-free survival (PFS), overall survival (OS), adverse events (AEs), dose reductions and discontinuations. Hazard ratios (HRs) and risk differen","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-03-15T13:49:05.108Z","creation":"2025-04-06T14:10:21.631Z"},"accession":"S-EPMC9874016","cross_references":{"pubmed":["36713467"],"doi":["10.1016/j.eclinm.2023.101824"]}}